These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34729800)

  • 21. Analysis of cobalt for human sports drug testing purposes using ICP- and LC-ICP-MS.
    Knoop A; Planitz P; Wüst B; Thevis M
    Drug Test Anal; 2020 Nov; 12(11-12):1666-1672. PubMed ID: 33142033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budesonide use and misuse in sports: Elimination profiles of budesonide and metabolites after intranasal, high-dose inhaled and oral administrations.
    Coll S; Monfort N; Matabosch X; Papakonstantinou K; Pérez-Mañá C; Mateus JA; Ventura R
    Drug Test Anal; 2020 May; 12(5):629-636. PubMed ID: 31306564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls.
    Eichner D; Van Wagoner RM; Brenner M; Chou J; Leigh S; Wright LR; Flippin LA; Martinelli M; Krug O; Schänzer W; Thevis M
    Drug Test Anal; 2017 Nov; 9(11-12):1768-1778. PubMed ID: 28378453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use.
    Mareck U; Fusshöller G; Geyer H; Huestis MA; Scheiff AB; Thevis M
    Drug Test Anal; 2021 Mar; 13(3):539-549. PubMed ID: 33125823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of tolvaptan and its metabolites in sports drug testing by high-performance liquid chromatography coupled to tandem mass spectrometry.
    Rzeppa S; Viet LN
    Drug Test Anal; 2016 Oct; 8(10):1090-1094. PubMed ID: 26768215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS.
    Thomas A; Geyer H; Kamber M; Schänzer W; Thevis M
    J Mass Spectrom; 2008 Jul; 43(7):908-15. PubMed ID: 18563864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes.
    Höppner S; Delahaut P; Schänzer W; Thevis M
    J Pharm Biomed Anal; 2014 Jan; 88():649-59. PubMed ID: 24239904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of GnRH and its synthetic analogues' abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers.
    Zvereva I; Dudko G; Dikunets M
    Drug Test Anal; 2018 Apr; 10(4):711-722. PubMed ID: 28777889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The atypical excretion profile of meldonium: Comparison of urinary detection windows after single- and multiple-dose application in healthy volunteers.
    Görgens C; Guddat S; Bosse C; Geyer H; Pop V; Schänzer W; Thevis M
    J Pharm Biomed Anal; 2017 May; 138():175-179. PubMed ID: 28213178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigations on carbon isotope ratios and concentrations of urinary formestane.
    Piper T; Fusshöller G; Emery C; Schänzer W; Saugy M
    Drug Test Anal; 2012 Dec; 4(12):942-50. PubMed ID: 22354842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfate metabolites as alternative markers for the detection of 4-chlorometandienone misuse in doping control.
    Balcells G; Gómez C; Garrostas L; Pozo ÓJ; Ventura R
    Drug Test Anal; 2017 Jul; 9(7):983-993. PubMed ID: 27686240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of mepitiostane metabolites in human urine by liquid chromatography/tandem mass spectrometry for sports drug testing.
    Okano M; Sato M; Kojima A; Kageyama S
    J Pharm Biomed Anal; 2015 Nov; 115():236-44. PubMed ID: 26247800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of urine analysis and dried blood spot analysis for the detection of ephedrine and methylephedrine in doping control.
    Kojima A; Nishitani Y; Sato M; Kageyama S; Dohi M; Okano M
    Drug Test Anal; 2016 Feb; 8(2):189-98. PubMed ID: 25869885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of two glucuronides resistant to enzymatic hydrolysis as markers of testosterone oral administration.
    Kotronoulas A; Gomez-Gomez A; Segura J; Ventura R; Joglar J; Pozo OJ
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):212-218. PubMed ID: 27328448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls.
    Thevis M; Thomas A; Möller I; Geyer H; Dalton JT; Schänzer W
    Rapid Commun Mass Spectrom; 2011 Aug; 25(15):2187-95. PubMed ID: 21710598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of new exemestane metabolites by liquid chromatography interfaced to electrospray-tandem mass spectrometry.
    de Albuquerque Cavalcanti G; Carius Garrido B; Dias Leal F; Costa Padilha M; Mazzarino M; de la Torre X; Botre F; Radler de Aquino Neto F
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):248-54. PubMed ID: 21924357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-throughput screening for various classes of doping agents using a new 'dilute-and-shoot' liquid chromatography-tandem mass spectrometry multi-target approach.
    Guddat S; Solymos E; Orlovius A; Thomas A; Sigmund G; Geyer H; Thevis M; Schänzer W
    Drug Test Anal; 2011; 3(11-12):836-50. PubMed ID: 22135086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
    Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
    Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of ¹³C/¹² C ratios of endogenous urinary 5-amino-imidazole-4-carboxamide 1β-D-ribofuranoside (AICAR).
    Piper T; Thomas A; Baume N; Sobolevsky T; Saugy M; Rodchenkov G; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2014 Jun; 28(11):1194-202. PubMed ID: 24760559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.